HealthMatch, which helps researchers run clinical trials for oncology and chronic conditions, is also opening its platform to help recruit coronavirus trial patients for free to expedite COVID-19 research in Australia.
Writing on the HealthMatch website, company Founder and CEO Manuri Gunawardena said that with the coronavirus pandemic gripping the nation- and with global trials now well underway - the importance of clinical testing is urgent, and for many countries, critical.
“In response to the COVID-19 Pandemic, HealthMatch will provide patient recruitment services free to all organisations (public and private) for COVID-19 research. This includes pharmaceutical, biotechnology, NFP, Universities, Government and other organisations unified in the fight against COVID-19,” Gunawardena said.
“HealthMatch has developed a free, public global clinical trial tracker available here.
“We know that this is a difficult time for many researchers and patients who have also had their clinical trials on other conditions disrupted, delayed or abandoned. When hospitals begin to function as normal and clinical trials resume, we will be there to continue to support our patients, doctors and scientists to get new medicines out to those that need them most.”
“The devastating impact of the COVID-19 (SARS-CoV-2) pandemic is being felt globally, highlighting the importance of medical research and the critical role it plays in our fight against deadly pathogens.
“From the beginning of 2020, we have seen unprecedented levels of international cooperation between individual researchers, public & private institutions and governments in the race to find a vaccine or treatment for COVID-19.
“The tireless efforts of the individuals involved combined with the focus and resources of the public and private institutions backing them, has meant significant progress has already been made in both our understanding and ability to treat COVID-19.
“These joint efforts are yielding significant results with several new diagnostic tests now in production, repurposed medications and innovative vaccines entering clinical trials, the power of working together in this time of crisis is being seen firsthand.
“Several potential treatments and vaccine candidates are now reaching clinical trials, a vital process to ensure both the efficacy and safety of these breakthroughs before being made available for wider use amongst the population.
“At HealthMatch, we know that this is a difficult time for many researchers and patients who have also had their clinical trials focussing on other conditions disrupted, delayed or abandoned. The anxiety we are all feeling waiting for the results of COVID-19 Clinical trials is the exact feeling many cancer patients and chronic illness sufferers feel when new medicine is delayed in clinical trials.
“We hope that as a wider take away from COVID-19, the spotlight is directed to the importance of supporting medical research and clinical trials to find new medicines for the many medical conditions for which we have no treatments.
“And when this all settles, we’ve successfully flattened the curve and hospitals can begin to function again and clinical trials resume, we will be there to continue to support our patients, doctors and scientists to get new medicines out to those that need them most,” Gunawardena concluded.